Happy New Year!

2026 will be an exciting year for Entrada, and we want to start it by sharing our plans, activities and key milestones for the year ahead.

You can read today's news release by clicking the button below—or get the highlights by reading the newly-refreshed **Updates on Clinical Studies** section.

As always, if you have any questions, email us at PatientAdvocacy@entradatx.com or find us in person at the **Community Events** at the bottom of this email!

Read our January 8, 2026, news release for more details

Updates on Clinical Studies

Enabled by our Endosomal Escape Vehicle (EEV™) platform, we are working to quickly advance our lead programs for people living with Duchenne who are exon 44, 45, 50 or 51 skipping amenable. Read on for our progress.

Exon 44 Skipping Amenable Community

ELEVATE-44-201 Study: Continuing to Enroll Participants

The ELEVATE-44-201 study is a global, randomized, double-blind placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-44 in ambulatory children and young adults living with Duchenne who are amenable to exon 44 skipping. The study is taking place in the U.K., Belgium, Italy and Spain.

The first cohort has completed dosing in the double-blind, placebo-controlled portion of the study and participants will be transitioning to the "open label" portion of the study, where they will all receive ENTR-601-44. An independent Data Monitoring Committee (DMC) has reviewed initial data from the eight participants enrolled in the first cohort and supports study continuation without any modifications. The study will continue to enroll for the second and third cohorts.

We are on track to report data from the first cohort in the second quarter (April-June) of 2026, the second cohort by the end of 2026, and the third cohort to follow. To learn more about the study, visit www.elevate44study.com.

ELEVATE-44-102 Study: On Track to Start in the First Half of 2026

The ELEVATE-44-102 study is a randomized, double-blind placebo-controlled* Phase 1b study evaluating the safety and tolerability of ENTR-601-44 in non-ambulatory and ambulatory adults living with Duchenne who are amenable to exon 44 skipping. The study will take place in the U.S. In December 2025, the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease Designation to ENTR-601-44.

Exon 45 Skipping Amenable Community

ELEVATE-45-201 Study: Continuing to Enroll Participants

The ELEVATE-45-201 study is a global, randomized, double-blind placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-45 in ambulatory children and young adults living with Duchenne who are amenable to exon 45 skipping. The study is taking place in the U.K., the Netherlands, Belgium, Italy and Spain.

We have dosed the first participant in this study and expect to share data from the first cohort of participants in mid-2026, with data from the second and third cohorts to follow. To learn more about the study, visit www.elevate45study.com.

Exon 50 Skipping Amenable Community

ELEVATE-50-201 Study: Received Regulatory Authorization to Initiate in the U.K.

The ELEVATE-50-201 study is a global, randomized, double-blind placebo-controlled* Phase 1/2 study evaluating the safety, tolerability and effectiveness of ENTR-601-50 in ambulatory children and young adults living with Duchenne who are amenable to exon 50 skipping.

We have received regulatory authorization from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics committee to initiate the study in the U.K. We plan to submit regulatory applications in the EU for ELEVATE-50-201 in the second half of 2026 and begin the study by the end of 2026, following the first cohort data readouts from our ELEVATE-44-201 and ELEVATE-45-201 studies.

Exon 51 Skipping Amenable Community

We remain on track to submit global regulatory filings for a Phase 1/2 study of ENTR-601-51 in 2026.

**A placebo looks like a study drug but does not have any medicine in it. Researchers use placebos to help make sure any changes in participants' health are actually caused by the study drug.*

Upcoming Community Events

We support, participate in and hold events to connect with the community and work toward solutions together. Here's what we're up to for the next few months:

February 6-7:
Duchenne UK New Horizons Conference
(London, UK)

February 10-12:
TREAT-NMD International Conference
(Lisbon, Portugal)

February 28-March 2:
Parent Project APS International Conference
(Rome, Italy)

March 8-10:
PPMD Annual Advocacy Conference
(Washington DC, USA)

March 8-11:
MDA Clinical and Scientific Conference
(Orlando, FL)

We'd love to connect with you!

Contact Sarah Friedhoff, our Head of Patient Advocacy, at PatientAdvocacy@entradatx.com.

This document includes forward-looking statements that involve risks and uncertainties. These statements are not guarantees of future results and should not be used for investment decisions.

To help make this newsletter accessible to more readers, we offer automated translations of our original English content. Because these translations are produced by software, they may contain grammatical mistakes, differences in interpretation, or unintended mistranslations.

Follow us on social for news, updates and more.

Want to change how you receive these emails?
You can update your preferences or unsubscribe
Privacy Notice

Start typing